Oxykodón/Naloxón Stada Arzneimittel (Naloxone, Oxycodone)

Naloxone, the active ingredient in Oxykodón/Naloxón Stada Arzneimittel, is an opioid antagonist presented as a combination formulation for oral use. It is used together with oxycodone to manage moderate to severe pain in adults when a balanced analgesic effect and opioid‑overdose protection are desired.

GNH USA supplies Oxykodón/Naloxón Stada Arzneimittel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Oxycodone/naloxone is indicated for pain management within the opioid analgesic pathway, providing relief while reducing abuse potential. - Chronic cancer pain: improves analgesia while lowering opioid‑induced constipation. - Severe postoperative pain: offers strong pain control with built‑in opioid antagonism. - Chronic non‑cancer pain requiring long‑term opioid therapy: maintains pain relief and mitigates bowel side effects. - Acute severe trauma pain: delivers rapid analgesia with reduced risk of respiratory depression. - Palliative care pain: ensures comfort while protecting against opioid‑related adverse events.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Constipation: reduced bowel motility despite naloxone's protective effect. - Dizziness or light‑headedness: transient vestibular sensations. - Headache: mild cranial discomfort. - Dry mouth: decreased salivation. - Fatigue: general sense of tiredness.

Serious or Rare Side Effects: - Respiratory depression: severe reduction in breathing rate. - Severe hypotension: marked drop in blood pressure. - Hepatotoxicity: liver enzyme elevations or injury. - Allergic reactions: rash, pruritus, or anaphylaxis. - Seizures: rare neurologic events. - Urinary retention: difficulty emptying the bladder.

When prescribing Oxykodón/Naloxón Stada Arzneimittel, clinicians should consider several safety aspects. - Assess renal and hepatic function: adjust therapy if impairment is present. - Monitor for signs of opioid dependence: watch for misuse behaviors. - Evaluate respiratory status: especially in opioid‑naïve patients. - Use caution in the elderly: increased sensitivity to sedative effects. - Avoid abrupt discontinuation: taper to prevent withdrawal. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Oxycodone/naloxone may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): heightened risk of respiratory depression. - MAO inhibitors: can precipitate severe hypertension or serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase oxycodone plasma levels.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine): may alter oxycodone metabolism. - Diuretics: can exacerbate hypotension. - Anticholinergic agents: increase risk of constipation despite naloxone.